Approved, no longer marketed Sexual & reproductive

Histrelin

Histrelin is a GnRH agonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it was approved by the FDA but is no longer marketed in the United States.

Regulatory status

Histrelin was approved by the FDA, but the product is no longer marketed in the United States.

An approval that has been discontinued is not the same as a drug you can obtain today.

From the FDA label

What Histrelin is approved to treat

(histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Histrelin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on sexual & reproductive

Start with your own numbers.

Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.

See the OPTML Score

Educational reference only. This page explains what has been published about Histrelin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides